66 related articles for article (PubMed ID: 8060135)
1. [Effects of SN-38 in combination with other anticancer agents against Dauji cells].
Akutsu M; Suzuki K; Tsunoda S; Kano Y; Miura Y
Gan To Kagaku Ryoho; 1994 Aug; 21(10):1607-11. PubMed ID: 8060135
[TBL] [Abstract][Full Text] [Related]
2. Effects of CPT-11 in combination with other anti-cancer agents in culture.
Kano Y; Suzuki K; Akutsu M; Suda K; Inoue Y; Yoshida M; Sakamoto S; Miura Y
Int J Cancer; 1992 Feb; 50(4):604-10. PubMed ID: 1537625
[TBL] [Abstract][Full Text] [Related]
3. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells.
Pei XH; Nakanishi Y; Takayama K; Bai F; Kawasaki M; Tsuruta N; Mizuno K; Hara N
Anticancer Drugs; 1997 Mar; 8(3):231-7. PubMed ID: 9095327
[TBL] [Abstract][Full Text] [Related]
4. Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines.
Kano Y; Akutsu M; Suzuki K; Yoshida M
Leuk Res; 1993 Feb; 17(2):113-9. PubMed ID: 8429687
[TBL] [Abstract][Full Text] [Related]
5. The effects of ICRF-154 in combination with other anticancer agents in vitro.
Kano Y; Narita T; Suzuki K; Akutsu M; Suda K; Sakamoto S; Miura Y
Br J Cancer; 1992 Aug; 66(2):281-6. PubMed ID: 1503899
[TBL] [Abstract][Full Text] [Related]
6. [Effects of carboplatin combination with etoposide against leukemia/lymphoma cell lines].
Akutsu M; Suzuki K; Tsunoda S; Kano Y
Gan To Kagaku Ryoho; 1996 Feb; 23(3):297-302. PubMed ID: 8712822
[TBL] [Abstract][Full Text] [Related]
7. Effects of mitoxantrone in combination with other anticancer agents on a human leukemia cell line.
Kano Y; Suzuki K; Akutsu M; Suda K
Leukemia; 1992 May; 6(5):440-5. PubMed ID: 1593909
[TBL] [Abstract][Full Text] [Related]
8. [Combination therapy of CPT-11, a camptothecin derivative, with various antitumor drugs against L 1210 leukemia].
Furuta T; Yokokura T
Gan To Kagaku Ryoho; 1991 Mar; 18(3):393-402. PubMed ID: 1900684
[TBL] [Abstract][Full Text] [Related]
9. Effects of amsacrine in combination with other anticancer agents in human acute lymphoblastic leukemia cells in culture.
Kano Y; Sakamoto S; Kasahara T; Akutsu M; Inoue Y; Miura Y
Leuk Res; 1991; 15(11):1059-66. PubMed ID: 1961009
[TBL] [Abstract][Full Text] [Related]
10. In vitro augmentation of antitumor effect in combination with CPT-11 and CDDP for human colorectal cancer.
Tsunoda T; Tanimura H; Hotta T; Tani M; Iwahashi M; Ishimoto K; Tanaka H; Matsuda K; Yamaue H
J Surg Oncol; 2000 Jan; 73(1):6-11. PubMed ID: 10649271
[TBL] [Abstract][Full Text] [Related]
11. Effects of 13-hydroxy SM5887 in combination with other anticancer agents on human tumor cell lines.
Takagi T; Yazawa Y; Suzuki K; Yamauchi Y; Kano Y
Invest New Drugs; 1996; 14(4):357-63. PubMed ID: 9157070
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Izumi T; Kobayashi H; Mano H; Furukawa Y
Invest New Drugs; 2007 Feb; 25(1):31-40. PubMed ID: 16865529
[TBL] [Abstract][Full Text] [Related]
13. Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines.
Yazawa Y; Takagi T; Asakura S; Suzuki K; Kano Y
J Orthop Sci; 1999; 4(3):231-7. PubMed ID: 10370165
[TBL] [Abstract][Full Text] [Related]
14. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells.
Osaki S; Nakanishi Y; Takayama K; Pei XH; Ueno H; Hara N
Cancer Gene Ther; 2000 Feb; 7(2):300-7. PubMed ID: 10770640
[TBL] [Abstract][Full Text] [Related]
15. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines.
Kano Y; Akutsu M; Tsunoda S; Mori K; Suzuki K; Adachi KI
Cancer Chemother Pharmacol; 1998; 42(2):91-8. PubMed ID: 9654107
[TBL] [Abstract][Full Text] [Related]
16. [Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent--the in vitro evaluation].
Oguro M; Seki Y
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1556-61. PubMed ID: 1651682
[TBL] [Abstract][Full Text] [Related]
17. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line.
Masumoto N; Nakano S; Esaki T; Tatsumoto T; Fujishima H; Baba E; Nakamura M; Niho Y
Anticancer Res; 1995; 15(2):405-9. PubMed ID: 7763013
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
[TBL] [Abstract][Full Text] [Related]
19. In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.
Kimura T
Osaka City Med J; 2001 Jun; 47(1):33-41. PubMed ID: 11556390
[TBL] [Abstract][Full Text] [Related]
20. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
